Levetiracetam tablets (Kiplan) are used for the additional treatment of partial seizures in adults and children with epilepsy over 4 years old. Below are the instructions for levetiracetam tablets that I compiled. Welcome to read them.
Levetiracetam Tablets Product Introduction
Generic name: Levetiracetam Tablets
Manufacturer: UCB Pharma S.A. (Belgium)
Approval number: Registration certificate number H20110409
Drug specification: 0.25g*30 tablets
Drug price: ￥160 yuan
Levovir Instructions for Racetam Tablets
Common name: Levetiracetam Tablets
Trade name: Levetiracetam Tablets (Kaipulan)
English name: Levetiracetam Tablets
Pinyin full code ZuoYiLaXiTanPian (KaiPuLan)
The active ingredient of levetiracetam tablets (KaiPuLan) is levetiracetam, and its chemical name is (S) -?-Ethyl-2-oxo-1-pyrrolidineacetamide.
Chemical name: (S)-?-ethyl-2-oxo-1-pyrrolidineacetamide
Molecular formula: C8H14N2O2
Molecular weight: 170.21
Characteristics: Levetiracetam tablets (Kiplan) are oval film-coated tablets (250mg is blue tablet, 500mg is yellow tablet, and 1000mg is white tablet). After removing the coating, they all appear White.
Indications/Function Indications: It is used as an add-on treatment for partial seizures in adults and children with epilepsy over 4 years old.
Specification model: 0.5g*30s
Usage and dosage: Take orally. It needs to be swallowed with an appropriate amount of water and is not affected by eating. The initial treatment dose for adults (18 years old) and adolescents (12 to 17 years old) weighing less than 50 kg is 500 mg each time, twice a day. Based on clinical efficacy and tolerability, the daily dose may be increased to 1500 mg twice daily. Dosage changes should be increased or decreased by 500mg/time every 2-4 weeks, twice daily.
Adverse reactions 1. Systemic reactions and discomfort at the administration site, common: fatigue. 2. Nervous system discomfort, common: drowsiness, forgetfulness, ataxia, convulsions, dizziness, headache, excessive movement, tremor. 3. Mental and psychological changes, common: irritability, depression, emotional instability, hostility, insomnia, neurosis, personality changes, and abnormal thinking. Post-marketing adverse event reports: abnormal behavior, aggression, irritability, anxiety, confusion, hallucinations, agitation, psychosis, suicide, suicidal ideation, suicide attempt. However, there are insufficient data to estimate their incidence or establish a causal relationship. 4. Gastrointestinal discomfort, common: diarrhea, indigestion, nausea, and vomiting. 5. Metabolic and nutritional disorders, common: loss of appetite. The risk of anorexia is increased when patients are also taking topiramate. 6. Discomfort of the ears and labyrinth system, common: dizziness. 7. Eye discomfort, common: diplopia. 8. Injuries, poisoning and subsequent complications, common: accidental injuries. 9. Infection and contagion, common: infection. 10. Respiratory system discomfort, common: increased coughing. 11. Abnormal changes in the skin and subcutaneous tissue, common: rash. Post-marketing adverse event reports: Alopecia, which in some cases resolved spontaneously after discontinuation of the drug. 12. Abnormal changes in the blood system and lymphatic system, adverse events reported on the market: leukopenia, neutropenia, pancytopenia, thrombocytopenia, but there is not enough data to estimate their incidence or establish causality.
It is contraindicated in patients who are allergic to levetiracetam or to pyrrolidone derivatives or any other ingredients.
Notes 1. According to current clinical practice, if you need to stop taking levetiracetam tablets (Kiplan), it is recommended to discontinue the drug gradually. 2. In clinical studies, it was reported that 14 adults and children taking levetiracetam had an increase in seizure frequency of more than 25%, but among adults and children taking placebo, 26 and 21 patients each had an increase in seizure frequency. 3. For patients with liver function impairment, please refer to [Usage and Dosage]. For patients with severe liver damage, renal function should be checked first and then adjusted. 4. There is currently no research on the impact of medication on machine control and vehicle driving abilities. 5. Due to individual differences in sensitivity, drowsiness or other central nervous system symptoms may occur during the initial stage of treatment or after the dose is increased. Therefore, for these patients who need to take medications, it is not recommended to operate machines that require skill, such as driving a car or operating machinery.
Medication for children is unclear.
Medication for elderly patients is unclear.
Medication for Pregnant and Lactating Women There is currently no data on the use of levetiracetam tablets (Kiplan) by pregnant women. Animal experiments have proven that the drug has certain reproductive toxicity. The potential danger to humans is currently unknown. Pregnant women should not use levetiracetam unless necessary. Sudden discontinuation of antiepileptic treatment may worsen the condition and be harmful to both mother and fetus. Animal tests have shown that levetiracetam can be excreted in breast milk, so it is not recommended that patients breastfeed while taking the drug.
Drug interactions 1. In vitro data show that at concentrations above the Cmax level obtained within the therapeutic dose range, levetiracetam and its major metabolites are neither human liver cytochrome P450 nor epoxy. is an inhibitor of hydrolase or uridine diphosphate-glucosidase, nor is it a high-affinity substrate for them. Therefore, pharmacokinetic interactions are less likely to occur. In addition, levetiracetam does not affect the in vitro glucosidase action of valproic acid. 2. Levetiracetam has a low plasma protein binding rate ([10]) and is not prone to clinically significant interactions due to competition with other drugs for protein binding sites. 3. Pharmacokinetic screening between drugs was evaluated in clinical pharmacokinetic studies (phenytoin, sodium valproate, oral contraceptives, digoxin, warfarin, and probenecid) and placebo-controlled clinical trials. Potential pharmacokinetic interactions. 4. Drug-drug interactions between levetiracetam and other antiepileptic drugs (AEDs)
Drug overdose 1. Symptoms: drowsiness, agitation, aggression, decreased level of consciousness, and breathing were observed. Inhibition and coma. 2. First aid measures for drug overdose. After acute drug overdose, vomiting or gastric lavage should be used to empty the stomach. There is currently no antidote for levetiracetam. Treatment requires symptomatic treatment and may also include hemodialysis. The effect of dialysis elimination: levetiracetam 60, main metabolite 74.
Pharmacology and Toxicology 1. Pharmacology: Levetiracetam is a pyrrolidone derivative, and its chemical structure is not related to existing anti-epileptic drugs. The exact mechanism of levetiracetam's antiepileptic effects is unknown. The antiepileptic effects of levetiracetam have been evaluated in various animal models of epilepsy. Levetiracetam has no inhibitory effect on simple seizures induced by large stimulation of electrical current or multiple agonists, and shows only weak activity in sublarge stimulation and threshold tests. However, protective effects were observed against generalized seizures secondary to focal seizures induced by pilocarpine and kainic acid, two chemical convulsants that mimic the characteristics of complex partial seizures with secondary generalized seizures in some individuals. . Levetiracetam has inhibitory effects on both the kindling process and the kindling state in the rat kindling model of complex partial seizures. The predictive value of these animal models for specific types of epilepsy in humans is unclear. 2. Toxicology: The results of Levetiracetam Ames test, CHO/HGPRT locus mammalian cell gene mutation test, CHO cell chromosome aberration test, and mouse micronucleus test were all negative. The results of Ames test of levetiracetam hydrolyzate and main human metabolite (ucbL057) and mouse lymphoma test were negative.
Pharmacokinetics 1. Levetiracetam is an extremely soluble and highly permeable compound.
Metabolism is linear, with small intra- and inter-individual differences. Multiple administration does not affect its clearance rate. Levetiracetam tablets (Kepulan) have no gender, racial or circadian differences. Pharmacokinetic studies of levetiracetam tablets (Kepulan) showed that the pharmacokinetic data in healthy volunteers and patients were comparable. 2. Due to the complete absorption and linear relationship of levetiracetam, its plasma concentration can be predicted based on the oral dose mg/kg, so there is no need to monitor the plasma concentration of levetiracetam.
Storage sealed.
Packaging: 0.5g*30s/box.
Valid for 24 months
Approval number H20110410
Manufacturer UCB Pharma S.A. (Belgium)
Levetiracetam tablets Efficacy and role of (Kaipulan) Levetiracetam tablets (Kaipulan) are used for the additional treatment of partial seizures in adults and children with epilepsy over 4 years old.
Frequently Asked Questions about Taking Levetiracetam Tablets
Pregnant women need to be very careful when taking medication when they are sick. Levetiracetam tablets can be used as an add-on treatment for partial seizures in adults and children with epilepsy over 4 years old. So, can pregnant women take levetiracetam tablets?
It is not recommended that pregnant women take levetiracetam tablets. There is currently no data on pregnant women taking levetiracetam tablets, and animal tests have proven that the drug has certain reproductive toxicity. The potential danger to humans is currently unknown. Pregnant women should not use levetiracetam unless necessary. Sudden discontinuation of antiepileptic treatment may worsen the condition and be harmful to both mother and fetus. Animal experiments have shown that levetiracetam can be excreted in breast milk, so it is not recommended that patients breastfeed while taking the drug.
Levetiracetam is a pyrrolidone derivative whose chemical structure is not related to existing anti-epileptic drugs. The exact mechanism of levetiracetam's antiepileptic effects is unknown. The antiepileptic effects of levetiracetam have been evaluated in various animal models of epilepsy. Levetiracetam has no inhibitory effect on simple seizures induced by maximal stimulation with electrical current or multiple agonists and shows only weak activity in submaximal stimulation and threshold tests.
However, protective effects were observed against generalized seizures secondary to focal seizures induced by pilocarpine and kainic acid, two chemical convulsants that can mimic secondary generalized seizures in some individuals. Characteristics of complex partial seizures. Levetiracetam has inhibitory effects on both the kindling process and the kindling state in the rat kindling model of complex partial seizures. The predictive value of these animal models for specific types of epilepsy in humans is unclear.
In vitro and in vivo experiments show that levetiracetam inhibits epileptiform burst discharges in the hippocampus without affecting the excitability of normal neurons, suggesting that levetiracetam may selectively inhibit epileptiform bursts. Hypersynchrony of firing discharges and seizure propagation.